Double-blind trial of feprazone and phenylbutazone in acute gout.
A double-blind trial was carried out in 24 patients with acute gout to compare the efficacy and tolerance of feprazone, a non-steroidal anti-inflammatory drug, with that of phenylbutazone. Patients received 800 mg of either drug daily for 2 days and then 600 mg daily for up to 8 days. The results of patient assessment showed there was no significant difference between the two groups in time taken either to significant improvement or to final resolution of the gout attack. No side-effects were reported with either drug.
D000208:Acute Disease; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D011298:Feprazone / Q000627:therapeutic use*; D006073:Gout / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010653:Phenylbutazone / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D011298:Feprazone; D010653:Phenylbutazone